A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Phase 2

Withdrawn

• Conditions: Diffuse Large B-Cell Lymphoma
• Interventions: Drug: bendamustine; Drug: rituximab; Drug: navitoclax

• Registration Number: NCT01423539
• Lead Sponsor: Genentech, Inc.

Brief Summary

This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse large B-cell lymphoma. Patients will be randomized to receive navitoclax in addition to bendamustine and rituximab or bendamustine and rituximab alone for 6 cycles.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-08-24
• Study First Submitted QC: 2011-08-24
• Study First Posted: 2011-08-26
• Study Start: 2011-10
• Primary Completion: 2014-02
• Study Completion: 2014-02
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-01
• Last Update Posted: 2016-11-02

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Histologically documented diagnosis of diffuse large B-cell lymphoma
• Patients must have relapsed or developed progressive disease following salvage therapy, or must have relapsed or progressed following initial therapy and in the opinion of the investigator are medically unfit to receive high dose chemotherapy with autologous stem cell transplant (SCT) or other salvage therapy of higher priority
• Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2
• Patients who have undergone STC must be more than 100 days from autologous stem cell infusion prior to first dose of study drug, must have recovered from any transplant related toxicity and must have adequate bone marrow function as defined by protocol independent of any growth factor support
• Patients who have not undergone SCT must have adequate bone marrow function as defined by protocol independent of any growth factor support
• Adequate coagulation, renal and hepatic function

Exclusion Criteria

• Refractory DLBCL
• History of other malignancies within 2 years prior to initiation of study treatment except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, low-grade localized prostate cancer treated surgically with curative intent or one that carries a good prognosis, in situ ductal carcinoma of the breast treated with lumpectomy (with and without radiation) with curative intent
• Active infection requiring parenteral antibiotics or antiviral or antifungal agents
• Inherited or acquired bleeding diathesis, anticoagulant drugs or drugs that inhibit platelet function, underlying conditions that predisposes to abnormal bleeding, or refractoriness to platelet transfusions
• Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, or ventricular tachyarrhythmias requiring medication within 1 year prior to the initiation of study treatment
• Positive for hepatitis B, hepatitis C or HIV infection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A	bendamustine	-
A	rituximab	-
B	bendamustine	-
B	navitoclax	-
B	rituximab	-

Primary Outcome Measures

Name	Time	Method
Progression-free survival (time from randomization to progression, relapse or death of any cause)	up to approximately 33 months

Secondary Outcome Measures

Name	Time	Method
Safety: Incidence of adverse events	approximately 33 months
Duration of response	approximately 33 months
Clinical response rates (complete response/partial response/stable disease)	approximately 33 months
Overall survival	approximately 33 months